Valeant: FDA Issues Complete Response Letter for Duobrii

Monday, June 18, 2018 | Healthcare Trends , Psoriasis , Product Launches and Updates , Ortho Dermatologics , Valeant NJ

Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. has received a Complete Response Letter (CRL) from the US FDA regarding the company's New Drug Application (NDA) for DUOBRII (halobetasol propionate and tazarotene) (IDP-118) lotion in the treatment of plaque psoriasis.

Open in New Window Next Story


You must be logged in to leave a comment.